skip to main content
UK Health Security Agency

97-18

97-18

Catalogue No.

21062327

Cell Line Name

97-18

Cell Line Description

Established from a urothelial (formerally known as transitional cell) carcinoma (TCC) in the bladder (Stage T2 muscle-invasive, Grade 3). The patient had 1 recurrence.

 

Also known as TCC 97-18 or 97-18-I (where I means Invasive) and comes from the same patient in which cell line 97-21 was established (also known as TCC 97-21 and 97-21 M (Metastatic).

 

Cell line classified as neither male or female by the depositor. ECACC STR-PCR authentication data has detected a Y chromosome, which matches the depositor STR-PCR profile. Earl et al (2015) (Table 1) show that the Y chromosome was detected and Zuiverloon et al (2018) (Table 2) states that the gender was not determined.

Characteristics

Tissue of Origin

Bladder

Morphology

Epithelial

DNA profile (STR Profile)

Amelogenin: X, Y
CSF1PO: 11, 12
D3S1358: 14, 16
D5S818: 12, 13
D7S820: 9, 10
D8S1179: 13, 13
D13S317: 12, 12
D16S539: 9, 11
D18S51: 12, 18
FGA: 20, 23
Penta D: 9, 9
Penta E: 12, 15
TH01: 9, 9.3
TPOX: 11, 11
vWA: 16, 16

Applications

To identify genetic biomarkers to stratify TCCs for appropriate clinical management.

Disease

Transitional cell carcinoma

Culture Conditions

Subculture Routine

Incubation at 37oC with 5% CO2.

 

Split sub-confluent log-phase cultures with 0.05% Trypsin/EDTA solution. Neutralise trypsin/EDTA solution with media containing 10% Foetal Bovine serum (FBS) or Soya bean trypsin inhibitor (SBTI) solution at ratio of 1:10, for low serum cultures.

 

Establish new cultures at 1-4 x 104 cells per cm2.

 

Cell lines are relatively slow growing under these culture conditions.

Culture Medium

Hams F12 + 1% FBS + 1x Insulin-Transferrin-Selenium + 1μg/ml hydrocortisone + 1x Non-essential amino acids 100x + 2mM L-Glutamine

 

Cryopreserve cells in growth medium containing 10% DMSO.

Growth Mode

Adherent

Additional Info

Depositor

Margaret Knowles, Division of Molecular Medicine, Leeds Institute of Medical Research at St James’ St James' University Hospital, Beckett Street, Leeds LS9 7TF. Deposited on behalf of Dr Catherine Reznikoff , Departments of Human Oncology, University of Wisconsin Comprehensive Cancer Centre and University of Wisconsin Medical School.

Country of Origin

United States

Hazard Group (ACDP)

Hazard Group (ACDP) 2

Applications

References

Yeager, T R et al. “Overcoming cellular senescence in human cancer pathogenesis.” Genes & development vol. 12,2 (1998): 163-74. doi:10.1101/gad.12.2.163 PMID: 9436977

Bibliography

Zuiverloon, Tahlita C M et al. “Systematic Review: Characteristics and Preclinical Uses of Bladder Cancer Cell Lines.” Bladder cancer (Amsterdam, Netherlands) vol. 4,2 169-183. 26 Apr. 2018, doi:10.3233/BLC-180167 PMID: 29732388

 

Earl, Julie et al. “The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.” BMC genomics vol. 16,1 403. 22 May. 2015, doi:10.1186/s12864-015-1450-3 PMID: 25997541

 

Ross, Rebecca L et al. “Identification of mutations in distinct regions of p85 alpha in urothelial cancer.” PloS one vol. 8,12 e84411. 18 Dec. 2013, doi:10.1371/journal.pone.0084411 PMID: 24367658

 

Taylor, Claire F et al. “Frequent inactivating mutations of STAG2 in bladder cancer are associated with low tumour grade and stage and inversely related to chromosomal copy number changes.” Human molecular genetics vol. 23,8 (2014): 1964-74. doi:10.1093/hmg/ddt589 PMID: 24270882

 

Platt, Fiona M et al. “Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research vol. 15,19 (2009): 6008-17. doi:10.1158/1078-0432.CCR-09-0898 PMID: 19789314

 

Jebar, Adel H et al. “FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.” Oncogene vol. 24,33 (2005): 5218-25. doi:10.1038/sj.onc.1208705 PMID: 15897885

Available Formats

  • Frozen
  • DNA-5µg (100ng/µl)

If use of this culture results in a scientific publication, it should be cited in the publication as: 97-18 (ECACC 21062327).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country.

 

ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.